8-K: KalVista Reports Strong EKTERLY Launch, Exceeds Revenue Estimates

KalVista Pharmaceuticals announced preliminary Q4 and full-year 2025 revenue for EKTERLY, exceeding expectations with strong patient adoption and international expansion.

Summary

• KalVista Pharmaceuticals reported preliminary global net revenue of approximately $35 million for the fourth quarter ended December 31, 2025.
• Preliminary global net revenue for the eight-month transition period (full year) ended December 31, 2025, was approximately $49 million.
• The company received 1,318 patient start forms in the US through December 31, 2025, reflecting rapid adoption of EKTERLY.
• 580 unique prescribers have been activated in the US through December 31, 2025.
• Prescription refills surpassed initial prescriptions as the primary revenue driver in Q4 2025, with some activity potentially reflecting demand pulled forward ahead of the holidays.
• KalVista partnered with Multicare Pharmaceuticals, LLC for exclusive commercialization rights of sebetralstat in Latin America (Brazil, Argentina, Colombia, and Mexico), marking its third commercial partnership in 10 months.
• Enrollment in the Phase 3 KONFIDENT-KID trial for pediatric HAE patients (2-11 years) was completed a full year ahead of schedule.
• A new drug application (NDA) for the pediatric HAE population is expected to be filed in the third quarter of 2026, with a US launch anticipated in 2027.

Sentiment

Score: 9

Explanation: The filing presents overwhelmingly positive news regarding the commercial launch of EKTERLY, with strong preliminary revenue figures, rapid patient and prescriber adoption, successful international expansion, and accelerated progress in the pediatric clinical program. The tone is highly optimistic, and the operational achievements are significant.

Positives

• Preliminary global net revenue of $35 million for Q4 2025 and $49 million for the full year 2025 demonstrates a strong commercial launch for EKTERLY.
• Rapid patient adoption is evidenced by 1,318 patient start forms and 580 unique prescribers in the US through December 2025.
• The shift to refills surpassing initial prescriptions in Q4 2025 indicates growing real-world familiarity and patient satisfaction with EKTERLY.
• Strong early adoption is observed in Germany, mirroring positive US trends, and new commercial partnerships in Latin America expand global reach.
• Completion of enrollment in the KONFIDENT-KID pediatric trial a full year ahead of schedule accelerates the potential market expansion for EKTERLY.
• EKTERLY is approved in seven key global markets (US, EU, UK, Switzerland, Australia, Singapore, Japan), providing a broad foundation for international growth.

Negatives

• The financial information provided is preliminary and unaudited, subject to completion of financial closing procedures and audit adjustments, which may differ materially from actual results.
• Management noted some effects from seasonal variability in demand, which could imply fluctuations in future quarters.

Risks

• Actual results may differ materially from preliminary financial information due to financial closing procedures and audit adjustments.
• The success of commercialization efforts for EKTERLY, including revenues from sales, is subject to risks and uncertainties.
• There is a risk in the ability to successfully obtain additional foreign regulatory approvals for sebetralstat.
• The safety and efficacy of sebetralstat and other product candidates may not meet expectations.
• The timing and results of clinical trials, including KONFIDENT-S and KONFIDENT-KID, are subject to uncertainty.
• The ability to commence or complete ongoing clinical studies may be impacted by unforeseen factors.
• The ability of EKTERLY to effectively treat HAE as anticipated is a forward-looking statement subject to risks.
• Global business or macroeconomic conditions, including inflation, rising interest rates, instability in the global banking system, and geopolitical conflicts, could adversely affect business and operations.
• The ability to protect intellectual property is a continuous risk factor.

Future Outlook

The company expects to expand EKTERLY into other major international markets during 2026. An NDA filing for pediatric HAE patients aged 2-11 years is anticipated in Q3 2026, with a US launch expected in 2027, aiming to make EKTERLY a foundational therapy for HAE management worldwide. The US market for HAE treatment is projected to grow from $650 million to $1.5 billion with increased treatment rates driven by oral options. KalVista also plans to leverage its capabilities to develop or acquire additional innovative therapies for rare diseases, while evaluating partnered opportunities for its internal oral Factor XIIa inhibitor program.

Management Comments

• Ben Palleiko, CEO: "We are extremely pleased with our performance since launching EKTERLY in July, which reflects steady execution, growing utilization, and continued momentum across our business."
• Ben Palleiko, CEO: "Fundamental demand has remained strong, with some effects from seasonal variability, and we are encouraged by the continued high level of interest in switching to EKTERLY."
• Ben Palleiko, CEO: "With EKTERLY rapidly emerging as the preferred on-demand HAE treatment, we remain committed to making it accessible to all people living with HAE, including pediatric patients aged 2-11 years, where we expect to file a new drug application in the third quarter."
• Nicole Sweeny, Chief Commercial Officer: "Demand for EKTERLY remains steady, supported by strong prescriber engagement and positive patient and provider experiences."
• Nicole Sweeny, Chief Commercial Officer: "Utilization has increased consistently since we launched in July, and we are particularly encouraged by the continued growth of patient refills, which now make up the majority of total sales."

Industry Context

EKTERLY (sebetralstat) is positioned as the first and only oral on-demand treatment for hereditary angioedema (HAE), a rare disease characterized by unpredictable swelling attacks. This offers a significant advantage over existing injectable on-demand therapies, which often lead to treatment delays, underutilization, and high patient burden. The introduction of an oral option is expected to fundamentally reshape the HAE market, increasing treatment rates and potentially expanding the total addressable market from $650 million to $1.5 billion in the US.

Comparison to Industry Standards

• EKTERLY is the first and only oral on-demand treatment for HAE, addressing a significant unmet need compared to existing injectable or intravenous on-demand therapies.
• Injectable on-demand therapies previously left key needs unaddressed, with an average wait time of 3.8 hours for adults and 7.7 hours for adolescents to treat an attack, and 1/3 to 1/2 of patients not carrying on-demand treatment outside the home.
• EKTERLY's clinical data shows a median time to treatment of 10 minutes and median time to beginning of symptom relief of 1.3 hours for laryngeal, abdominal, and LTP breakthrough attacks, demonstrating rapid action comparable to or better than some injectables.
• The KONFIDENT-KID trial data for pediatric patients (2-11 years) shows a median time to treatment of 30 minutes and median time to symptom relief of 1.5 hours, with no issues swallowing, making it a more patient-friendly option than injectables for children.
• The company estimates EKTERLY accounts for 15% of US HAE patients (out of an estimated 9,000 total), indicating strong initial market penetration for a new oral therapy in a market previously dominated by injectables.

Stakeholder Impact

• Shareholders: Positive impact due to strong preliminary revenue, rapid market adoption, and accelerated pipeline development, suggesting potential for increased shareholder value.
• Patients (HAE): Significant positive impact by providing the first and only oral on-demand treatment, improving access, reducing treatment burden, and expanding treatment options to pediatric populations.
• Prescribers (HCPs): Positive impact by offering an effective and convenient oral treatment option for HAE, leading to high engagement and repeat prescriptions.
• Employees: Positive impact from strong company performance, growth, and expansion into new markets and patient populations.

Next Steps

• Complete financial closing procedures and audit of financial statements for the eight-month transition period ended December 31, 2025.
• Expand EKTERLY into other major international markets during 2026.
• File a new drug application (NDA) for EKTERLY in pediatric HAE patients aged 2-11 years in the third quarter of 2026.
• Anticipate US launch of EKTERLY for pediatric patients aged 2-11 years in 2027.
• Continue to leverage global capabilities and infrastructure to develop, acquire, or in-license additional innovative therapies targeting rare diseases with significant unmet needs.
• Evaluate partnered opportunities for the internal oral Factor XIIa inhibitor program.

Key Dates

Recommendation

The filing indicates a highly successful commercial launch for EKTERLY, with preliminary revenue figures exceeding expectations and demonstrating strong market penetration. The rapid adoption by patients and prescribers, coupled with strategic international expansion and accelerated progress in the pediatric program, positions KalVista for significant future growth. The company is addressing a substantial unmet medical need with a differentiated product, and the positive operational momentum suggests a strong trajectory for revenue and market share expansion. While preliminary, the results are robust enough to warrant a 'strong buy' recommendation for investors seeking exposure to a growing rare disease pharmaceutical company.

Keywords

EKTERLY, sebetralstat, hereditary angioedema, HAE, oral on-demand treatment, pharmaceuticals, rare disease, biotechnology, Q4 2025 revenue, patient start forms, clinical trial, pediatric HAE, NDA filing